Human Papillomavirus (HPV) is well known as one of the major risk HPVDNAChip(R) factors for cervical cancer. The purpose of this study is to know HPV genotype distribution in women with normal cervix, precancerous lesion, and invasive cervical cancer by HPVDNAChip(R) test. In addition, the result of HPVDNAChip(R) test was compared with Hybrid Capture II (TM) system for HPV detection.

One hundred forty nine patients were included in this study. 57 women had normal cervix, 59 women had precancerous lesion, and 33 women had invasive cervical cancer. We tested them with two method for detection of Human Papillomavirus (HPV) by HPVDNAChip(R) test and Hybrid Capture II (TM) system. Hybrid Capture II (TM) test can detect same high-risk HPVs (16/18/31/33/35/39/45/51/52/56/58/59/68) with HPVDNAChip(R) test which can detect additional 66 & 69 high risk types of HPV.

Both methods for the detection of HPV were useful tests. The correlation between the results of two methods was very significant (kappa value 0.721 [p<0.01]). Positive Hybrid Capture II (TM) test and negative HPVDNAChip(R) test group were 18 women (12.1%) and average Hybrid Capture II (TM) titer value of this group was 120.7+/-233.0 (mean+/-SD), positive Hybrid Capture II (TM) test and positive HPVDNAChip(R) test group were 84 women (54.4%) and average titer was 448.1+/-732.8. The Hybrid Capture II (TM) test showed a sensitivity of 94.6% and a specificity of 78.9% and the HPVDNAChip(R) test showed a sensitivity of 83.7% and a specificity of 89.5%. HPVDNAChip(R) test detected total 14 genotype of HPV. HPV-16 was 28.8% (15/59) in precancerous lesion and 48.5% (19/33) in invasive cancer, most common in both groups. Next common type HPV-58 was 25.4% (12/59) in precancerous lesion and 9.1% (3/33) in invasive cancer.

HPVDNAChip(R) test is very sensitive and effective method for detection of Human Papillomavirus (HPV) infection as Hybrid Capture II (TM)test. In comparison with Hybrid Capture II (TM) test, HPV genotype and multiple HPV infection information can be given by HPVDNAChip(R) test. Further study will be needed to know the value of screening of cervical cancer by HPVDNAChip(R) test in future.